Seven indications to treat a wide range of patients with multiple myeloma1
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) is approved to treat a wide range of adult patients with multiple myeloma, including those who are newly diagnosed, and those who are relapsed or refractory.1
DPd=DARZALEX FASPRO® (D) + pomalidomide (P) + dexamethasone (d); DRd=DARZALEX FASPRO® (D) + lenalidomide (R) + dexamethasone (d); DVd=DARZALEX FASPRO® (D) + bortezomib (V) + dexamethasone (d); DVMP=DARZALEX FASPRO® (D) + bortezomib (V) + melphalan (M) + prednisone (P); DVTd=DARZALEX FASPRO® (D) + bortezomib (V) + thalidomide (T) + dexamethasone (d); PI=proteasome inhibitor.
*Daratumumab includes both daratumumab and hyaluronidase-fihj (DARZALEX FASPRO®) for subcutaneous injection and daratumumab (DARZALEX®) for intravenous infusion. Daratumumab and hyaluronidase-fihj for subcutaneous injection has different dosing and administration instructions compared to daratumumab for intravenous infusion.
†See nccn.org for definitions of NCCN Categories of Preference.
‡Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V4.2021. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed January 5, 2021. To view the most recent and complete version of the guideline, go online to www.nccn.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
NCCN Preferred Category 1
Daratumumab (DARZALEX®)* in combination with lenalidomide and dexamethasone (Rd) is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred Category 1† therapeutic option for newly diagnosed, transplant-ineligible multiple myeloma‡